WO2011027800A1
2010-08-26
Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor
WO2010147234A1
2010-06-16
Diarylamide-spirodiamine derivative
WO2010123150A1
2010-04-21
2-aryl imidazoline derivatives
WO2010119984A1
2010-04-14
3-aryl or heteroaryl-substituted indole derivative
WO2010117090A1
2010-04-09
Novel isoquinolinyloxymethyl heteroaryl derivatives
WO2010117084A1
2010-04-07
Novel isoquinoline derivatives
WO2010076887A1
2009-12-22
Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
WO2010050456A1
2009-10-27
Piperidine compound having di- or tri-arylmethyl structure
CA2733646A1
2009-08-03
Acetyl pyrrolidinyl indole derivative
CA2734981A1
2009-08-03
Oxotetrahydrofuran-2-yl-benzimidazole derivative
WO2010013633A1
2009-07-23
Methods for prediction of rb status and sensitivity to plk1 inhibitor of cell
AU2009261248A1
2009-06-11
Spirodiamine-diarylketoxime derivative
WO2009151997A1
2009-06-02
Process for producing bicycloaniline derivatives
ZA200903127B
2009-05-06
Novel aminopyrimidine derivatives as PLK1 inhibitors
WO2009125798A1
2009-04-08
Method for screening of pharmaceutical candidate substance for treatment of cancer in which hedgehog pathway is activated
JP2010229093A
2009-03-27
New chemerin r agonist
EP2272841A1
2009-03-26
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009110510A1
2009-03-04
Alkylaminopyridine derivative
CA2714215A1
2009-02-18
Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2009099086A1
2009-02-04
3-substituted sulfonyl piperazine derivative
